**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2016-17/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | TORY 60 TABLETS | | REF. NO: NDQD201509253 |
| **DATE RECEIVED:** 03.09.2015 | **LABEL CLAIM:** | Each film coated tablet contains Etoricoxib INN 60 mg. | |
| **BATCH NO.:** 506002 | **PRESENTATION:** | Light pink coloured, caplet shaped, biconvex faced tablets, single scored on both faces, packed in a blister pack of 5 tablets and 6 such strip in a unit box. | |
| **MGF. DATE:** Jun. 2015 | **MANUFACTURER:** | SQUARE Pharmaceuticals Ltd. | |
| **EXP. DATE:**  May 2017 | **ADDRESS:** | BANGLADESH. | |
| **CLIENT REF NO:** | **CLIENT:** | Ace Pharmaceuticals Ltd, P.O BOX 29787-00202, Nairobi, KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than x% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC | Manufacturer's Method | RT of the major peak in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT 6.8 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | UV | Manufacturer's Method | After 45 Mins | 99.5% (RSD=0.8%, n=6) | **COMPLIES** |
| **Assay** | HPLC | Manufacturer's Method | 90.0-110.0% | 97.8% (RSD=0.5%, n=9) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | MR. D. MOENGA |  | DATE:21-01-2016 |
| ANALYST: | DR. S. MUTERU |  | DATE:11-02-2016 |
| ANALYST: | ERNEST MBAE |  | DATE:02-15-2016 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:02-22-2016 |